uniQure (QURE) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChart

uniQure Revenue Highlights


Latest Revenue (Y)

$15.84M

Latest Revenue (Q)

$2.29M

Main Segment (Y)

License revenues

uniQure Revenue by Period


uniQure Revenue by Year

DateRevenueChange
2023-12-31$15.84M-85.12%
2022-12-31$106.48M-79.68%
2021-12-31$524.00M1296.82%
2020-12-31$37.51M415.23%
2019-12-31$7.28M-35.48%
2018-12-31$11.28M-13.91%
2017-12-31$13.11M-47.78%
2016-12-31$25.10M143.57%
2015-12-31$10.30M80.87%
2014-12-31$5.70M40.19%
2013-12-31$4.06M100.00%
2012-12-31-100.00%
2011-12-31--

uniQure generated $15.84M in revenue during NA 2023, up -85.12% compared to the previous quarter, and up 140.40% compared to the same period a year ago.

uniQure Revenue by Quarter

DateRevenueChange
2024-09-30$2.29M-79.44%
2024-06-30$11.13M31.13%
2024-03-31$8.48M26.85%
2023-12-31$6.69M375.41%
2023-09-30$1.41M-41.91%
2023-06-30$2.42M-54.52%
2023-03-31$5.33M-94.82%
2022-12-31$102.75M6990.75%
2022-09-30$1.45M191.55%
2022-06-30$497.00K-72.27%
2022-03-31$1.79M-96.89%
2021-12-31$57.69M2800.50%
2021-09-30$1.99M-99.57%
2021-06-30$463.87M102073.57%
2021-03-31$454.00K-98.67%
2020-12-31$34.09M1805.31%
2020-09-30$1.79M16.55%
2020-06-30$1.53M1375.96%
2020-03-31$104.00K-96.04%
2019-12-31$2.63M150.96%
2019-09-30$1.05M-57.72%
2019-06-30$2.47M117.78%
2019-03-31$1.14M-29.35%
2018-12-31$1.61M-48.92%
2018-09-30$3.15M3.21%
2018-06-30$3.05M-12.31%
2018-03-31$3.48M34.60%
2017-12-31$2.58M14.34%
2017-09-30$2.26M-54.27%
2017-06-30$4.94M48.81%
2017-03-31$3.32M-63.28%
2016-12-31$9.05M24.69%
2016-09-30$7.25M65.48%
2016-06-30$4.38M-0.87%
2016-03-31$4.42M19.61%
2015-12-31$3.70M4.31%
2015-09-30$3.54M95.67%
2015-06-30$1.81M51.10%
2015-03-31$1.20M-26.00%
2014-12-31$1.62M27.54%
2014-09-30$1.27M-10.65%
2014-06-30$1.42M-11.65%
2014-03-31$1.61M24.13%
2013-12-31$1.30M-25.70%
2013-09-30$1.74M76.93%
2013-06-30$986.16K100.00%
2013-03-31-100.00%
2012-12-31--

uniQure generated $2.29M in revenue during Q3 2024, up -79.44% compared to the previous quarter, and up 94.43% compared to the same period a year ago.

uniQure Revenue Breakdown


uniQure Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
License revenues$2.76M$100.00M$517.40M--
Collaboration revenues$2.25M$4.77M$6.60M--
License revenues from related party-----
License Revenue From Related Party---$32.97M$4.99M
Collaborative Revenue From Related Party---$136.00K$2.29M
Collaborative Revenue---$59.00K-
License---$4.35M-

uniQure's latest annual revenue breakdown by segment (product or service), as of Dec 23: License revenues (55.07%), and Collaboration revenues (44.93%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Mar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
License revenues$2.11M$1.87M$1.20M$1.97M$793.00K$55.00M--------------
Collaboration revenues$200.00K$7.13M$3.29M$1.54M$319.00K$388.00K$1.03M$1.45M$497.00K$1.79M$2.69M---------
License------------$462.40M-------
Collaborative Revenue-----------$1.99M$1.47M$454.00K------
Collaborative Revenue From Related Party--------------$61.00K$13.00K$5.00K$57.00K$1.14M$204.00K
License Revenue From Related Party--------------$29.61M$1.78M$1.53M$47.00K$1.48M$842.00K

uniQure's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: License revenues (91.35%), and Collaboration revenues (8.65%).

uniQure Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
AMLXAmylyx Pharmaceuticals$380.79M$416.00K
KNSAKiniksa Pharmaceuticals$270.26M$112.21M
STROSutro Biopharma$153.73M$25.71M
RGNXREGENXBIO$90.24M$24.20M
RYTMRhythm Pharmaceuticals$77.43M$29.08M
PTGXProtagonist Therapeutics$60.00M$4.67M
MRUSMerus$43.95M$11.77M
QUREuniQure$15.84M$2.29M
MGTXMeiraGTx$14.02M$10.91M
RNAAvidity Biosciences$9.56M$2.04M
PHATPhathom Pharmaceuticals$682.00K$16.35M
KRTXKaruna Therapeutics$654.00K-
GPCRStructure Therapeutics--
XFORX4 Pharmaceuticals-$560.00K
PCVXVaxcyte--
DAWNDay One Biopharmaceuticals-$20.07M
ABOSAcumen Pharmaceuticals--
INZYInozyme Pharma--
REPLReplimune Group--
RCKTRocket Pharmaceuticals--
SNDXSyndax Pharmaceuticals-$12.50M
TERNTerns Pharmaceuticals--
LRMRLarimar Therapeutics--
SLDBSolid Biosciences--

QURE Revenue FAQ


What is uniQure’s yearly revenue?

uniQure's yearly revenue for 2023 was $15.84M, representing a decrease of -85.12% compared to 2022. The company's yearly revenue for 2022 was $106.48M, representing a decrease of -79.68% compared to 2021. QURE's yearly revenue for 2021 was $524M, representing an increase of 1296.82% compared to 2020.

What is uniQure’s quarterly revenue?

uniQure's quarterly revenue for Q3 2024 was $2.29M, a -79.44% decrease from the previous quarter (Q2 2024), and a 62.54% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $11.13M, a 31.13% increase from the previous quarter (Q1 2024), and a 359.37% increase year-over-year (Q2 2023). QURE's quarterly revenue for Q1 2024 was $8.48M, a 26.85% increase from the previous quarter (Q4 2023), and a 59.34% increase year-over-year (Q1 2023).

What is uniQure’s revenue growth rate?

uniQure's revenue growth rate for the last 3 years (2021-2023) was -96.98%, and for the last 5 years (2019-2023) was 117.59%.

What are uniQure’s revenue streams?

uniQure's revenue streams in c 23 are License revenues, and Collaboration revenues. License revenues generated $2.76M in revenue, accounting 55.07% of the company's total revenue, down -97.24% year-over-year. Collaboration revenues generated $2.25M in revenue, accounting 44.93% of the company's total revenue, down -52.79% year-over-year.

What is uniQure’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of uniQure was License revenues. This segment made a revenue of $2.76M, representing 55.07% of the company's total revenue.